Abstract:BACKGROUND Anticoagulation is essential for the treatment and prevention of thromboembolic events. Current guidelines recommend direct oral anticoagulants (DOACs) over vitamin K antagonists in DOAC-eligible patients. The major complication of anticoagulation is serious or life-threatening haemorrhage, which may necessitate prompt haemostatic intervention. Reversal of DOACs may also be required for patients in need of urgent invasive procedures. This guideline from the European Society of Anaesthesiology and Intensive Care (ESAIC) aims to provide evidence-based recommendations and suggestions on how to manage patients on DOACs undergoing urgent or emergency procedures including the treatment of DOAC-induced bleeding. DESIGN A systematic literature search was performed, examining four drug comparators (dabigatran, rivaroxaban, apixaban, edoxaban) and clinical scenarios ranging from planned to emergency surgery with the outcomes of mortality, haematoma growth and thromboembolic complications. The GRADE (Grading of Recommendations, Assessment, Development and Evaluation) methodology was used to assess the methodological quality of the included studies. Consensus on the wording of the recommendations was achieved by a Delphi process. RESULTS So far, no results from prospective randomised trials comparing two active comparators (e.g. a direct reversal agent and an unspecific haemostatic agent such as prothrombin complex concentrate: PCC) have been published yet and the majority of publications were uncontrolled and observational studies. Thus, the certainty of evidence was assessed to be either low or very low (GRADE C). Thirty-five recommendations and clinical practice statements were developed. During the Delphi process, strong consensus (>90% agreement) was achieved in 97.1% of recommendations and consensus (75 to 90% agreement) in 2.9%. DISCUSSION DOAC-specific coagulation monitoring may help in patients at risk for elevated DOAC levels, whereas global coagulation tests are not recommended to exclude clinically relevant DOAC levels. In urgent clinical situations, haemostatic treatment using either the direct reversal or nonspecific haemostatic agents should be started without waiting for DOAC level monitoring. DOAC levels above 50 ng ml−1 may be considered clinically relevant necessitating haemostatic treatment before urgent or emergency procedures. Before cardiac surgery under activated factor Xa (FXa) inhibitors, the use of andexanet alfa is not recommended because of inhibition of unfractionated heparin, which is needed for extracorporeal circulation. In the situation of DOAC overdose without bleeding, no haemostatic intervention is suggested, instead measures to eliminate the DOACs should be taken. Due to the lack of published results from comparative prospective, randomised studies, the superiority of reversal treatment strategy vs. a nonspecific haemostatic treatment is unclear for most urgent and emergency procedures and bleeding. Due to the paucity of clinical data, no recommendations for the use of recombinant activated factor VII as a nonspecific haemostatic agent can be given. CONCLUSION In the clinical scenarios of DOAC intake before urgent procedures and DOAC-induced bleeding, practitioners should evaluate the risk of bleeding of the procedure and the severity of the DOAC-induced bleeding before initiating treatment. Optimal reversal strategy remains to be determined in future trials for most clinical settings.

Antidote vs. unspecific hemostatic agents for the management of direct oral anticoagulant-related bleeding in trauma

Direct oral anticoagulants in trauma patients

Direct Oral Anticoagulants Are a Potential Alternative to Low-Molecular-Weight Heparin for Thromboprophylaxis in Trauma Patients Sustaining Lower Extremity Fractures

Direct Oral Anticoagulants: Laboratory Challenges and Antidotes

Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH

Clinical guideline on reversal of direct oral anticoagulants in patients with life threatening bleeding

Management of bleeding in patients on direct oral anticoagulants in emergency department: where we are and where we are going

Management of Patients Treated with Direct Oral Anticoagulants in Clinical Practice and Challenging Scenarios

Direct Oral Anticoagulants: How Do These Drugs Work, How to Monitor, and What is Their Role in Orthopaedic Surgery.

The Challenging Scenarios of Life-Threatening Bleeding and Unplanned Invasive Procedures

Direct Oral Anticoagulants Versus Warfarin in Patients With Isolated Heparin‐Induced Thrombocytopenia or Heparin‐Induced Thrombocytopenia With Thrombosis

Specific Reversal Agents for Direct Oral Anticoagulants in Acute Stroke

The efficacy and safety of direct oral anticoagulants in the treatment of the acute phase of heparin-induced thrombocytopenia: A systematic review

Changes in the landscape of anticoagulation: a focus on direct oral anticoagulants

Reversal of oral anticoagulation in patients with acute intracerebral hemorrhage

Latest advances in the reversal strategies for direct oral anticoagulants

Is there a role for the laboratory monitoring in the management of specific antidotes of direct oral anticoagulants?

Management of DOAC-related bleeding in cancer patients: a single center-case series

Major bleeding complications in patients treated with direct oral anticoagulants: One-year observational study in a Paris Hospital

Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes: Meta-Analysis of Randomized Trials

Treatment of Venous Thromboembolism in Special Populations with Direct Oral Anticoagulants